Welcome to our dedicated page for Electrocore news (Ticker: ECOR), a resource for investors and traders seeking the latest updates and insights on Electrocore stock.
electroCore, Inc. (ECOR) is a leader in non-invasive vagus nerve stimulation therapies, providing innovative solutions for neurological conditions and wellness applications. This page serves as the definitive source for ECOR news, offering investors and professionals timely updates on regulatory developments, clinical research, and strategic initiatives.
Access curated press releases covering FDA clearances, partnership announcements, and financial results. Stay informed about advancements in gammaCore™ therapies for migraine treatment and TAC-STIM cognitive enhancement technologies. Our repository includes updates on international expansions, clinical trial outcomes, and product pipeline developments.
Bookmark this page for direct access to primary source materials from electroCore, including neuromodulation research breakthroughs and commercialization progress across healthcare and defense sectors. Regular updates ensure you maintain current awareness of ECOR's position in the evolving bioelectronic medicine landscape.
Rhea-AI Summary
electroCore, Inc. (ECOR) launches Truvaga Plus, a mobile app-enabled wellness product for stress management and overall wellbeing. The product offers features like mobile app connectivity, unlimited sessions, rechargeable design, and compact size. CEO Dan Goldberger highlights the innovative technology and benefits of Truvaga Plus.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.82%
Tags
-
Rhea-AI Summary
electroCore, Inc. (ECOR) has been granted two new U.S. patents related to its non-invasive vagus nerve stimulation (nVNS) technology by the United States Patent and Trademark Office (USPTO). The patents focus on stimulating nerves using a mobile device and treating central nervous system disorders like PTSD, fibromyalgia, anxiety, and TBI with electrical impulses. This development showcases the company's commitment to innovation and advancing bioelectronic medicine.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.76%
Tags
-
Rhea-AI Summary
electroCore, Inc. (ECOR) reported a significant increase in net sales for the full year 2023, reaching $16.0 million, an 87% growth over 2022. The company highlighted revenue growth across major channels, including prescription gammaCore devices and nonprescription products. Despite a rise in gross profit and a decrease in research and development expenses, the company faced increased operating expenses, resulting in a GAAP net loss of $18.8 million for 2023. Adjusted EBITDA net loss improved in Q4 2023 compared to Q4 2022. The company's cash position decreased from $18.0 million in 2022 to $10.6 million in 2023, despite raising $7.5 million through a direct offering in July 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.58%
Tags
Rhea-AI Summary
electroCore, Inc. (ECOR) announces participation in upcoming investor conferences. Chief Strategy Officer Joshua Lev and CEO Dan Goldberger to attend Roth and Needham conferences for investor meetings and company presentations.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.05%
Tags
-
Rhea-AI Summary
electroCore, Inc. (ECOR) to report Q4 and year-end 2023 financial results on March 13, 2024. Conference call scheduled to discuss the results.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.45%
Tags
-
Rhea-AI Summary
ElectroCore, Inc. (Nasdaq: ECOR) has announced the issuance of a patent by the United States Patent and Trademark Office related to treating disorders associated with viruses in the Coronaviridae family (COVID) using electrical impulses transcutaneously to the vagus nerve. The patent, U.S. Patent No. 11,894,148, covers systems and methods for treating patients with diseases associated with viruses.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.76%
Tags
Rhea-AI Summary
electroCore, Inc. (Nasdaq: ECOR) announced the issuance of a patent by the United States Patent and Trademark Office related to treating post-traumatic stress disorder (PTSD) using vagal nerve stimulation. The patent, U.S. Patent No. 11,865,329, covers methods for treating PTSD symptoms by applying electrical impulses to the vagus nerve for a specific duration and pulse pattern.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.74%
Tags
-
Rhea-AI Summary
electroCore, Inc. (Nasdaq: ECOR) has been granted two new U.S. patents related to its non-invasive vagus nerve stimulation (nVNS) technology. The patents, US Patent No. 11,850,056 and US Patent No. 11,854,695, were issued on December 26, 2023, and focus on remote therapy and patient monitoring, as well as medical devices for treating medical conditions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.62%
Tags
-
Rhea-AI Summary
electroCore, Inc. (Nasdaq: ECOR) announced the issuance of U.S. Patent No. 11,839,764 by the United States Patent and Trademark Office. The patent is related to a system for stimulating a nerve target in the head or neck of a patient for the treatment of various disorders, including primary headache. It involves a downloadable software program on a mobile device that controls the electrical impulses delivered by a stimulator to target nerves in the head or neck. This strengthens the company's intellectual property portfolio and positions them for the development of next-generation application-enabled products and devices.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.7%
Tags
Rhea-AI Summary
electroCore, Inc. (Nasdaq: ECOR) announces its Chief Medical Officer, Dr. Peter Staats, will host an analyst day on November 21, 2023, to discuss the potential of Vagus Nerve Stimulation with gammaCore™. The webinar will cover the nVNS mechanism of action and potential pipeline of indications using the company’s proprietary nVNS technology platform embodied in its gammaCore product.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.8%
Tags
Electrocore
Nasdaq:ECOR
ECOR Rankings
ECOR Stock Data
43.30M
5.87M
23.59%
12.63%
1.83%
Medical Devices
Electromedical & Electrotherapeutic Apparatus
United States
ROCKAWAY